Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Pharma pricing policy to hurt Cipla, Ranbaxy, Lupin: Vijay

      PN Vijay, Portfolio Manager, askpnvijay.com, says that companies like Cipla and Ranbaxy would be largely affected by the pricing policy because they have large presence in domestic life saving drugs space and to some extent affect will be seen on Lupin.

    • Glenmark Pharma may rally to Rs 490, says Mohindar

      Rahul Mohindar, Director of viratechindia.com is of the view that, in midcap space, Glenmark Pharma has fairly good potential. The stock is expected to rally to Rs 490.

    • Aashish Tater bullish on pharma sectors for long-term

      In an interview to CNBC-TV 18 Aashish Tater, Head of Research, Fortunewizard.com is bullish on Pharma sector. He discusses Glenmark and Cipla which are a buy for atleast a period of 12-18 months.

    • Expect 50% returns in Glenmark Pharma: Tater

      Expect 50% returns in Glenmark Pharma from current levels in next 12 months time, says Aashish Tater, Head of Research, Fortunewizard.com. We feel the expansion is going to continue even for next 3-4 quarters, which will be very rewarding for these kinds of companies. We have been bullish on Cipla, Glenmark, Wockhardt and we continue to do so.

    • Aluminium disappoints; bet on Cipla, Motherson: Tulsian

      SP Tulsian of sptulsian.com is not very satisfied with the performance of the aluminium segment of Hindalco. According to him, its copper division has done better and the overall performance of NALCO, Sterlite and the consolidated operations of BALCO has been poor, resulting in a poor aluminium segment performance.

    • Buy Glenmark Pharma on every dip: Sukhani

      Buy Glenmark Pharma on every dip, says Sudarshan Sukhani of s2analytics.com. It has gone through a small correction and that correction was over yesterday when it galloped up.

    • Glenmark Pharma can touch Rs 460: Agarwal

      Rajesh Agarwal, Eastern Financiers is of the view that Glenmark Pharma can touch Rs 460.

    • Buy Maruti Suzuki, M&M on any decline: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Maruti Suzuki, M&M on any decline.

    • Glenmark 'firing on all cylinders': JPMorgan

      GLENMARK-FIRING-ON-ALL-CYLINDERS-JPMORGAN:Glenmark 'firing on all cylinders' - J.P.Morgan

    • Buy Glenmark Pharma, says Mehraboon Irani

      Mehraboon Irani, Nirmal Bang Securities is of the view that one can buy Glenmark Pharma.

    • Check out: Darashaw's stock picks and wealth creators

      Regan F Homavazir continues to remain bullish on HDFC Bank because the longer term picture is extremely positive. He also likes J&K Bank.

    • Exit Orchid Chemicals, hold Glenmark Pharma: Sukhani

      Sudarshan Sukhani, s2analytics.com is of the view that exit Orchid Chemicals close to Rs 125-130. Stay invested in Glenmark Pharma.

    • Buy Shree Renuka, Glenmark Pharma: Sukhani

      Buy Shree Renuka, Glenmark Pharma, says Sudarshan Sukhani of s2analytics.com.

    • Go long on Glenmark Pharma: Salil Sharma

      One can go long on Glenmark Pharma with a stop loss of Rs 380, says Salil Sharma, Technical Analyst, Kapur Sharma & Co.

    • Sell Glenmark Pharma, says Sudarshan Sukhani

      Sell Glenmark Pharma, says Sudarshan Sukhani of s2analytics.com.

    • Buy Kotak Mahindra, Glenmark Pharma, MindTree: Ashish Kapur

      In CNBC-TV18's popular show Bull's Eye, Ashish Kapur, Investshoppe shares trading strategy of the day.

    • Bull's Eye: Buy DCB, Mindtree, Orchid; short Crompton

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Buy Pantaloons Retail, Glenmark Pharma: Agarwal

      In CNBC-TV18's popular show Bull's Eye, Abhishek Agarwal, Fortune Interfinance shares trading strategy of the day.

    • Bull's Eye: Short Ashok Leyland; buy Mah Satyam, CESC

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Glenmark Pharma a good pick: PN Vijay

      Glenmark Pharma is a good pick in the midcap pharma , says PN Vijay, Portfolio Manager.

    • Long on L&T, Glenmark; short Tata Steel: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can go long on L&T and Glenmark while Tata Steel is a sell.

    • Bull's Eye: Short Bombay Dyeing, ABB; buy RIL, Glenmark

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Go long in Glenmark Pharma on dip: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can go long in Glenmark Pharma on dip.

    • SP Tulsian positive on Glenmark Pharma

      SP Tulsian of sptulsian.com is positive on Glenmark Pharma.

    • Sukhani not upbeat on Glenmark Pharma

      Sudarshan Sukhani of s2analytics.com is not upbeat on Glenmark Pharma.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347